MedTrace Logo

Efficacy and Safety of AN2728 Topical Ointment to Treat Adolescents With Atopic Dermatitis

NCT01602341 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 86

Last updated 2017-03-06

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine the safety and efficacy of AN2728 Topical Ointment, 2% and 0.5%, administered once a day (QD) or twice a day (BID), in the treatment of adolescents with atopic dermatitis (AD)

Conditions

  • Dermatitis, Atopic

Interventions

DRUG

AN2728 Topical Ointment, 2% QD

AN2728 Topical Ointment, 2% QD

DRUG

AN2728 Topical Ointment, 0.5% QD

AN2728 Topical Ointment, 0.5% QD

DRUG

AN2728 Topical Ointment, 2% BID

AN2728 Topical Ointment, 2% BID

DRUG

AN2728 Topical Ointment, 0.5% BID

AN2728 Topical Ointment, 0.5% BID

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
12 Years
Max Age
17 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-08-31
Primary Completion
2013-01-31
Completion
2013-01-31

Countries

  • United States
  • Australia

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01602341 on ClinicalTrials.gov